Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Cardinal, McKesson to See Upgrades as Patents Expire

By Pharmaceutical Processing | September 19, 2011

A pending wave of patent expirations for top-selling drugs should lead to sustainable, improved profits and margins for pharmaceutical distributors like McKesson Corp. and Cardinal Health Inc., according to a Citi analyst.

Analyst George Hill said in a Monday morning research note he was upgrading shares of both companies to “Buy” from “Hold.” The analyst also raised price targets for the stock and earnings estimates.

Hill expects sales to contract as pharmaceuticals like Pfizer Inc.’s cholesterol fighter Lipitor, the world’s top-selling drug at nearly $11 billion a year, and Eli Lilly and Co.’s antipsychotic Zyprexa lose patent protection. But generics also should lead to margins and profit levels increasing faster than prices compress.

“Pharmaceutical wholesalers make razor-thin profit margins on the very-expensive branded drugs provided by a single manufacturer,” Hill wrote. “When these products begin to lose patent protection, both margin dollars and percentages rise drastically as competitors enter the market.”

Profit levels can be three to five times those generated on the original, branded drug when five or more manufacturers make a generic, the analyst said.

Hill raised target prices to $51 from $44 for Cardinal shares and to $101 from $90 for McKesson.

 

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards